Skip to main content

Clinical Trials Using Sirolimus

Review the clinical trials studying sirolimus on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 26

Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Status: Active
Location: 25 locations
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Status: Active
Location: 6 locations
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Location: 7 locations
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Status: Active
Location: 6 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients with Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Status: Active
Location: 2 locations
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Status: Active
Location: 2 locations
Sirolimus for Improving Hematopoietic Function in Patients with RUNX1 Familial Platelet Disorder
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ruxolitinib Based GVHD Prophylaxis Regimen before, during, and after Hematopoietic Cell Transplantation in Older Adult Patients with Acquired Aplastic Anemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Optimizing PTCy Dose and Timing
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
SC-DARIC33 for the Treatment of Relapsed or Refractory CD33+ Acute Myeloid Leukemia, PLAT-08 Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody with Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Intestinal or Multivisceral Transplantation for the Treatment of Unresectable Mucinous Carcinoma Peritonei, TRANSCAPE Trial
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Autophagy Therapeutics (Hydroxychloroquine, Nelfinavir, Metformin, Dasatinib, and Sirolimus) for the Treatment of Advanced Solid Tumors or Relapsed Prostate Cancer
Status: Temporarily Closed to Accrual
Location: Medical University of South Carolina, Charleston, South Carolina
Standard versus Low Dose Cyclophosphamide for Prevention of GVHD and Improvement in Quality of Life after Donor Stem Cell Transplant among Older Adults with Hematological Cancers
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients with Blood Cancer Undergoing a Donor Stem Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Comparing Cyclophosphamide, Sirolimus, Ruxolitinib to Cyclophosphamide, Sirolimus, Mycophenolate Mofetil after Allogeneic Stem Cell Transplantation for the Prevention of Graft versus Host Disease in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas